Business Wire

ORAL-B

24.8.2022 08:02:04 CEST | Business Wire | Press release

Share
Oral-B® Announces its Partnership with the iADH (International Association of Disability and Oral Health) to Help Make Oral Care More Accessible and for All

Oral-B, the leading innovator in oral health, announces partnership with the International Association of Disability and Oral Health (iADH) as part of the brand’s drive to make oral care more inclusive, accessible, and positive for people with disabilities, their caregivers, and everyone in between.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220823005621/en/

Approximately 166 million people in Europe are affected by a disability in some way and recent research reveals that a third (1/3) of those experience gum issues due to struggles with maintaining their oral health1 . Oral-B is on a mission to ensure that everybody has an equitable oral care experience - whether that be at the dentist practice, easily accessible and personalised tips and tricks or with the products that are used at home to maintain oral health.

Benjamin Binot, P&G Europe Oral Care Senior Vice President says: “As the leading innovator in oral health for over 70 years and the #1 dentist recommended brand, we recognise the importance of making oral care accessible to all – and continuously listen to people's experiences with disabilities to understand how we can help them. Through this work, we have learned that oral health care struggles amongst this audience are most common because many haven’t been taught the skills they need to brush their teeth effectively, they experience a sense of inevitability about their teeth deteriorating and may be especially anxious in the dentist’s chair. As a brand, we recognize our responsibility to help ensure that oral care is accessible to all and we are proud to partner with the iADH to work to improve the experience for people living with disabilities.”

The first step of this partnership is to co-create a ‘Positive Practices’ training program designed to train and educate dental practices on how to become more confident and inclusive when it comes to their patients.

Alison Dougall, iADH President says; “We are delighted to be working alongside Oral-B to address the significant oral health inequalities experienced by people with disabilities in Europe, through innovation, education, research and advocacy. By working together, we aim to make a positive difference to the oral care experience for people living with visible and nonvisible disabilities.

iADH exists to improve desired oral health outcomes for people with disabilities and Oral-B exists to create the best oral care outcomes by providing the most rewarding and enjoyable oral care experiences for everyone, everyday – given our shared values, it felt like a very natural fit when Oral-B approached us to come together in partnership”

The brand will also be present at this year’s Biennial iADH Congress 2022 in Paris to learn from the global members, who will be sharing their knowledge and experience to improve oral health outcomes for people with disabilities in a KOL workshop hosted by Oral-B. The findings gathered from the workshop will help to inform Positive Practices and ensure that the training programme is underpinned by insight to deliver the best outcome for change.

-ENDS-

About Oral-B

Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.

About The iADH (International Association of Disability and Oral Health)

The iADH is a global organization with over 8000 members from all sectors of health and social care interested in disability and oral health who work to share their scientific knowledge, clinical skills and collective experience to reduce barriers to care and improve oral health outcomes for people with disability

1 The Oral Health & Disability European Study, March 2022, Oral-B

For more information, please visit: https://www.oralb.co.uk/en-gb

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release

Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release

The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye